Alexander Supady1, Enya Weber2, Marina Rieder3, Achim Lother3, Tim Niklaus3, Timm Zahn3, Franziska Frech3, Sissi Müller3, Moritz Kuhl3, Christoph Benk4, Sven Maier4, Georg Trummer4, Annabelle Flügler3, Kirsten Krüger3, Asieb Sekandarzad3, Peter Stachon3, Viviane Zotzmann3, Christoph Bode3, Paul M Biever3, Dawid Staudacher3, Tobias Wengenmayer3, Erika Graf5, Daniel Duerschmied3. 1. Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany; Heidelberg Institute of Global Health, University of Heidelberg, Germany. Electronic address: alexander.supady@uniklinik-freiburg.de. 2. Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Medical Center, Faculty of Medicine, University of Freiburg, Germany. 3. Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Germany; Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Germany. 4. Department of Cardiovascular Surgery, Heart Center, Faculty of Medicine, University of Freiburg, Germany. 5. Institute of Medical Biometry and Statistics, Faculty of Medicine, University of Freiburg, Germany; Medical Center, Faculty of Medicine, University of Freiburg, Germany.
Abstract
BACKGROUND: We sought to clarify the benefit of cytokine adsorption in patients with COVID-19 supported with venovenous extracorporeal membrane oxygenation (ECMO). METHODS: We did a single-centre, open-label, randomised, controlled trial to investigate cytokine adsorption in adult patients with severe COVID-19 pneumonia requiring ECMO. Patients with COVID-19 selected for ECMO at the Freiburg University Medical Center (Freiburg, Germany) were randomly assigned (1:1) to receive cytokine adsorption using the CytoSorb device or not. Randomisation was computer-generated, allocation was concealed by opaque, sequentially numbered sealed envelopes. The CytoSorb device was incorporated into the ECMO circuit before connection to the patient circuit, replaced every 24 h, and removed after 72 h. The primary endpoint was serum interleukin-6 (IL-6) concentration 72 h after initiation of ECMO analysed by intention to treat. Secondary endpoints included 30-day survival. The trial is registered with ClinicalTrials.gov (NCT04324528) and the German Clinical Trials Register (DRKS00021300) and is closed. FINDINGS: From March 29, 2020, to Dec 29, 2020, of 34 patients assessed for eligibility, 17 (50%) were treated with cytokine adsorption and 17 (50%) without. Median IL-6 decreased from 357·0 pg/mL to 98·6 pg/mL in patients randomly assigned to cytokine adsorption and from 289·0 pg/mL to 112·0 pg/mL in the control group after 72 h. One patient in each group died before 72 h. Adjusted mean log IL-6 concentrations after 72 h were 0·30 higher in the cytokine adsorption group (95% CI -0·70 to 1·30, p=0·54). Survival after 30 days was three (18%) of 17 with cytokine adsorption and 13 (76%) of 17 without cytokine adsorption (p=0·0016). INTERPRETATION: Early initiation of cytokine adsorption in patients with severe COVID-19 and venovenous ECMO did not reduce serum IL-6 and had a negative effect on survival. Cytokine adsorption should not be used during the first days of ECMO support in COVID-19. FUNDING: None.
RCT Entities:
BACKGROUND: We sought to clarify the benefit of cytokine adsorption in patients with COVID-19 supported with venovenous extracorporeal membrane oxygenation (ECMO). METHODS: We did a single-centre, open-label, randomised, controlled trial to investigate cytokine adsorption in adult patients with severe COVID-19 pneumonia requiring ECMO. Patients with COVID-19 selected for ECMO at the Freiburg University Medical Center (Freiburg, Germany) were randomly assigned (1:1) to receive cytokine adsorption using the CytoSorb device or not. Randomisation was computer-generated, allocation was concealed by opaque, sequentially numbered sealed envelopes. The CytoSorb device was incorporated into the ECMO circuit before connection to the patient circuit, replaced every 24 h, and removed after 72 h. The primary endpoint was serum interleukin-6 (IL-6) concentration 72 h after initiation of ECMO analysed by intention to treat. Secondary endpoints included 30-day survival. The trial is registered with ClinicalTrials.gov (NCT04324528) and the German Clinical Trials Register (DRKS00021300) and is closed. FINDINGS: From March 29, 2020, to Dec 29, 2020, of 34 patients assessed for eligibility, 17 (50%) were treated with cytokine adsorption and 17 (50%) without. Median IL-6 decreased from 357·0 pg/mL to 98·6 pg/mL in patients randomly assigned to cytokine adsorption and from 289·0 pg/mL to 112·0 pg/mL in the control group after 72 h. One patient in each group died before 72 h. Adjusted mean log IL-6 concentrations after 72 h were 0·30 higher in the cytokine adsorption group (95% CI -0·70 to 1·30, p=0·54). Survival after 30 days was three (18%) of 17 with cytokine adsorption and 13 (76%) of 17 without cytokine adsorption (p=0·0016). INTERPRETATION: Early initiation of cytokine adsorption in patients with severe COVID-19 and venovenous ECMO did not reduce serum IL-6 and had a negative effect on survival. Cytokine adsorption should not be used during the first days of ECMO support in COVID-19. FUNDING: None.
Authors: Gerd Klinkmann; Thomas Wild; Benjamin Heskamp; Fanny Doss; Sandra Doss; Lubomir Arseniev; Krasimira Aleksandrova; Martin Sauer; Daniel A Reuter; Steffen Mitzner; Jens Altrichter Journal: Intensive Care Med Exp Date: 2022-06-16
Authors: Gabriele Eden; Julius J Schmidt; Stefan Büttner; Philipp Kümpers; Carsten Hafer; Alexandros Rovas; Benjamin Florian Koch; Bernhard M W Schmidt; Jan T Kielstein Journal: Crit Care Date: 2022-06-17 Impact factor: 19.334
Authors: Christina Scharf; Ines Schroeder; Michael Paal; Martin Winkels; Michael Irlbeck; Michael Zoller; Uwe Liebchen Journal: Ann Intensive Care Date: 2021-07-22 Impact factor: 6.925
Authors: Daniel Reynolds; Cristina Vazquez Guillamet; Aaron Day; Nicholas Borcherding; Rodrigo Vazquez Guillamet; José Alberto Choreño-Parra; Stacey L House; Jane A O'Halloran; Joaquín Zúñiga; Ali H Ellebedy; Derek E Byers; Philip A Mudd Journal: J Immunol Date: 2021-08-04 Impact factor: 5.426